Tigenix NV (TIG) Shares Sold by EAM Investors LLC

EAM Investors LLC trimmed its stake in Tigenix NV (NASDAQ:TIG) by 89.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 16,180 shares of the company’s stock after selling 139,706 shares during the period. EAM Investors LLC owned approximately 0.12% of Tigenix worth $386,000 as of its most recent SEC filing.

Shares of Tigenix NV (NASDAQ:TIG) opened at $22.49 on Friday. Tigenix NV has a 52 week low of $10.77 and a 52 week high of $25.72. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.37 and a quick ratio of 1.36.

A number of research analysts have commented on TIG shares. Canaccord Genuity reiterated a “buy” rating and set a $30.00 price target (up from $22.00) on shares of Tigenix in a research report on Wednesday, September 20th. Zacks Investment Research cut shares of Tigenix from a “hold” rating to a “sell” rating in a research report on Saturday, October 21st. Finally, BidaskClub cut shares of Tigenix from a “hold” rating to a “sell” rating in a research report on Friday, October 27th. Two analysts have rated the stock with a sell rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $24.50.

ILLEGAL ACTIVITY WARNING: This piece was posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://transcriptdaily.com/2017/11/26/tigenix-nv-tig-shares-sold-by-eam-investors-llc.html.

Tigenix Company Profile

TiGenix NV, a biopharmaceutical company, develops and commercializes therapeutics from its proprietary technology platforms of allogeneic or donor derived stem cells. Its stem cell programs are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory, and heart diseases.

Want to see what other hedge funds are holding TIG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tigenix NV (NASDAQ:TIG).

Receive News & Ratings for Tigenix NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tigenix NV and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply